Programma

welkom door voorzitters

Effect van kwaliteit op leven tijdens immuuntherapie

Lonneke van der Pol , Antoni van Leeuwenhoek

PREMIUM Project: Inzet van kunstmatige intelligentie voor het voorspellen van respons op immuuntherapie bij patiënten met uitgezaaid melanoom

Mark Schuiveling, UMC Utrecht

Neo adjuvant bij colorectal

Dr. Myriam Chalabi, internist-oncoloog, Antoni van Leeuwenhoek

Blaas

Michiel van der Heide, Antoni van Leeuwenhoek

What is new in early NSCLC (neoadjuvante immuuntherapie data)

Prof. dr. Egbert Smit, longarts, LUMC

O1 Activated cytotoxic tissue-resident CD8+ T cells in lamina propria and epithelium are a hallmark of immune checkpoint inhibitor colitis

Mick Van Eijs, UMC Utrecht

O2 Identification of individual volatile organic compounds in exhaled breath of advanced non-small cell lung cancer patients treated with (chemo-)immunotherapy: A proof-of-concept study

Alessandra Buma, Radboudumc

O3 Role of mutational signatures in immunotherapy benefit in lung cancer

Hylke Donker, UMCG

O4 Cost-effectiveness of a Predictive Biomarker in Pembrolizumab-Containing Treatment for Advanced Non-Small Cell Lung Cancer in The Netherlands: An Early Health Technology Assessment

Leila-sophie Otte, Radboudumc

O5 Identifying oligoprogression with cell-free DNA-based next-generation sequencing in non-small cell lung cancer patients treated with Immune Checkpoint Inhibitors

Pim Rozendal, UMCG

O6 Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment

Leila-sophie Otten, Radboudumc

n.t.b.

Cancer vaccines

Prof. Sjoerd van der Burg, Leiden University

Afsluiting voorzitters